Summary
We are searching for Kinetoplastida flap endonuclease (FEN) inhibitors as a base for potential therapeutics for parasite infections, for which there is significant unmet clinical need. Kinetoplastida are flagellated protists responsible for 3 neglected human diseases. We will target the FEN enzymes from Trypanasoma cruzi and Leishmania species, the organisms causing Chagas disease and leishmaniaisis respectively. FEN activity is crucial for the survival of all organisms tested so far from mouse to bacteria, including Trypanosoma. We will identify specific inhibitors of Kinetoplastida FENs as the basis for future development of urgently needed new therapeutics. This multidisciplinary structure-based inhibitor design project will involve in vitro and in silico screening, protein crystallization, rounds of inhibitor design and finally in vivo potency and toxicity experiments.
The project will be overseen by Prof Sayers who has 30 years of experience with nucleases and who has founded two spin-out companies. His group is complemented through collaboration with a parasitologist Dr Helen Price (20 years research experience), who has been actively involved in developing antiparasitic agents. The experienced researcher, who has a strong protein biochemistry and crystallography background, is returning to academic research after almost 4 years outside science. Ultimately, the experienced researcher is aspiring to an academic career in translational medicine rooted in state-of-the-art basic research but with the skills and experience to synergise with the pharmaceutical sector.
The project will be overseen by Prof Sayers who has 30 years of experience with nucleases and who has founded two spin-out companies. His group is complemented through collaboration with a parasitologist Dr Helen Price (20 years research experience), who has been actively involved in developing antiparasitic agents. The experienced researcher, who has a strong protein biochemistry and crystallography background, is returning to academic research after almost 4 years outside science. Ultimately, the experienced researcher is aspiring to an academic career in translational medicine rooted in state-of-the-art basic research but with the skills and experience to synergise with the pharmaceutical sector.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/843245 |
| Start date: | 01-02-2020 |
| End date: | 31-01-2023 |
| Total budget - Public funding: | 319 400,64 Euro - 319 400,00 Euro |
Cordis data
Original description
We are searching for Kinetoplastida flap endonuclease (FEN) inhibitors as a base for potential therapeutics for parasite infections, for which there is significant unmet clinical need. Kinetoplastida are flagellated protists responsible for 3 neglected human diseases. We will target the FEN enzymes from Trypanasoma cruzi and Leishmania species, the organisms causing Chagas disease and leishmaniaisis respectively. FEN activity is crucial for the survival of all organisms tested so far from mouse to bacteria, including Trypanosoma. We will identify specific inhibitors of Kinetoplastida FENs as the basis for future development of urgently needed new therapeutics. This multidisciplinary structure-based inhibitor design project will involve in vitro and in silico screening, protein crystallization, rounds of inhibitor design and finally in vivo potency and toxicity experiments.The project will be overseen by Prof Sayers who has 30 years of experience with nucleases and who has founded two spin-out companies. His group is complemented through collaboration with a parasitologist Dr Helen Price (20 years research experience), who has been actively involved in developing antiparasitic agents. The experienced researcher, who has a strong protein biochemistry and crystallography background, is returning to academic research after almost 4 years outside science. Ultimately, the experienced researcher is aspiring to an academic career in translational medicine rooted in state-of-the-art basic research but with the skills and experience to synergise with the pharmaceutical sector.
Status
CLOSEDCall topic
MSCA-IF-2018Update Date
28-04-2024
Images
No images available.
Geographical location(s)
